Floatz logo

Voriconazole

Obesity

OrsoBio, IncSmall moleculePhase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
59/ 100

Competitive context

360 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Cagrilintide
Novo Nordisk A/S
Phase 3BBB
Survodutide
Boehringer Ingelheim
Phase 3BBB
Sibutramine
Falquetomed
Phase 4BB

View all 50 →

Same molecule, other indications

Voriconazole is also rated in:

infectious diseaseDormant
BB
Indicative ·
66 / 100
View asset →
fungal infectious diseaseDormant
B
Indicative ·
63 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →